Related Experiment Video
Updated: Jun 1, 2026
09:57
Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy
Published on: September 20, 2024
Absence seizures associated with efavirenz initiation
Renate Strehlau1, Leigh Martens, Ashraf Coovadia
1Empilweni Services and Research Unit (ESRU), Rahima Moosa Mother and Child Hospital, Johannesburg, South Africa. renate.strehlau@wits.ac.za
The Pediatric Infectious Disease Journal
|June 3, 2011
Summary
Efavirenz treatment for pediatric HIV may cause central nervous system side effects like seizures. Genetic factors, such as the CYP2B6-516T/T genotype, can lead to high drug levels and seizures in children.
Area of Science:
- Pharmacogenomics
- Pediatric Neurology
- Infectious Diseases
Background:
- Efavirenz is a key antiretroviral medication for pediatric HIV.
- Central nervous system (CNS) side effects are known complications of efavirenz therapy.
- Understanding genetic influences on drug metabolism is crucial for optimizing pediatric HIV treatment.
Observation:
- A 5-year-old girl with perinatally acquired HIV developed new-onset absence seizures after initiating efavirenz.
- Her plasma efavirenz concentrations were found to be above the therapeutic range.
- The patient was identified as homozygous for the CYP2B6-516T/T genotype.
Findings:
- The CYP2B6-516T/T genotype is strongly associated with impaired efavirenz clearance.
- Elevated efavirenz levels in this patient likely contributed to the observed CNS toxicity.
- Discontinuation of efavirenz led to the resolution of absence seizures.
Implications:
- This case highlights the importance of considering pharmacogenetics in pediatric efavirenz treatment.
- Monitoring efavirenz levels and CYP2B6 genotype may help prevent CNS adverse events in children.
- Personalized medicine approaches can improve the safety and efficacy of HIV treatment in pediatric populations.
Related Concept Videos
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:20Seizures l: Introduction
Understanding seizures and epilepsy relies on key definitions that help in recognizing, classifying, and managing these disorders. These definitions provide a framework for recognizing, classifying, and managing seizure disorders.DefinitionsA seizure is a sudden, abnormal burst of electrical activity in the brain that can cause changes in awareness, movement, sensation, or behavior, depending on the area involved. Epilepsy is a chronic condition characterized by recurrent, unprovoked seizures,...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:24Epilepsy and Seizures: Overview
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:13Seizures: Classification
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
01:08Antiepileptic Drugs: Sodium Channel Blockers
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...